Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26103646 | 0.90 | AR (0.47) | ARPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25284895 | 0.84 | MTOR (0.41) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL25281610 | 0.83 | MTOR (0.39) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL25285387 | 0.82 | MAPK1 (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL30362219 | 0.82 | MIF (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL30362032 | 0.82 | MIF (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL26135768 | 0.82 | MIF (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL25239901 | 0.82 | MIF (0.38) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL30362103 | 0.81 | MIF (0.37) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL25280795 | 0.81 | MIF (0.37) | PDE4APDE4BPDE4CPDE4DMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221966-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4422746-A1 | RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076626-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076626-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221966-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | AR 751/4885PDE4A 711/4885PDE4B 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.